Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE Targeted BRAF and MEK inhibition has become an appropriate first-line treatment of BRAF-mutant advanced cutaneous melanoma. 31753111 2020
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. 31464610 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE As the current knowledge about pathogenesis, clinical and genetic features of cutaneous melanoma is not very clear, we aim to use bioinformatics to identify the potential key genes involved in the expression and mutation status of BRAF. 30925905 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 AlteredExpression disease BEFREE However, the CM energetic demand mainly depends on glycolysis, whose upregulation is strictly linked to constitutive activation of BRAF/MAPK pathway affected by BRAF<sup>V600E</sup> kinase mutant. 31362075 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE BRAF inhibitors substantially have impressive clinical efficacy in cutaneous melanoma. 28485171 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity. 31434983 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE There is no standard oncological treatment available for metastatic UM patients, and BRAF/MEK and immune checkpoint inhibitors show disappointing results when compared to cutaneous melanoma (CM). 31200439 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE Mitogen-activates protein kinase (MAPK) inhibitors, particularly MEK inhibitors, have shifted the treatment paradigm for metastatic BRAF-mutant cutaneous melanoma; however, oncologists, ophthalmologists, and patients have noticed different toxicities of variable importance. 30681641 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE A total of 46 adult lymph node-positive primary skin melanoma patients (23 BRAF-mutant and 23 BRAF-wild) with available information on the mutational status of the oncogene BRAF V600E were included in the analysis. 30997532 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE The use of selective BRAF inhibitors (BRAFi) has produced remarkable outcomes for patients with advanced cutaneous melanoma harboring a <i>BRAF<sup>V600E</sup></i> mutation. 31416844 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE Because the Mitogen-Activated Protein Kinase (MAPK) pathway plays such a significant role in melanoma development, we explore v-raf murine sarcoma viral oncogene homolog B (<i>BRAF)</i> and neuroblastoma RAS viral oncogene homolog (<i>NRAS)</i> mutations in mucosal melanoma and compare them to the mutation profiles in cutaneous melanoma and other tumors with <i>BRAF</i> and <i>NRAS</i> mutations. 31398831 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. 31391014 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE According to clinical trials, BRAF kinase inhibitors in combination with MEK kinase inhibitors are among the most promising chemotherapy regimens for the treatment of advanced BRAF-mutant melanoma, though the rate of BRAF mutation gene-bearing cutaneous melanoma is limited, especially in the Asian population. 31514399 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cutaneous melanoma have been significantly revised over the past few years in response to emerging data on immune checkpoint inhibitor therapies and BRAF-targeted therapy. 30959471 2019
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE BRAF inhibitors target the BRAF-V600E/K mutated kinase, the driver mutation found in 50% of cutaneous melanoma. 30429474 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE BRAF is the most frequently mutated gene in skin melanoma. 30347273 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE To identify the dermoscopic features associated with BRAF mutation in cutaneous melanoma and to evaluate a model capable of predicting BRAF mutations on the basis of dermoscopic and clinicopathologic features that are easily accessible in normal clinical practice. 29307636 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE BRAF and MEK inhibitors have demonstrated significant survival benefits for patients with cutaneous melanoma. 30205280 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE Metastatic uveal melanoma (MUM) does not harbor typically targetable mutations, e.g., BRAF as in cutaneous melanoma. 29433557 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE Compared to CM, which showed frequent mutations in known driver genes (BRAF 50.0%, NRAS 29.2%), MM displayed lower mutation frequencies (BRAF; 12.2%, p < 0.001, NRAS; 17.1%), and was significantly more enriched for triple wild-type (no mutations in BRAF, RAS, or NF1, 70.7% vs 25.0%, p < 0.001), IGF2R mutation (31.7% vs 6.3%, p = 0.002), and KIT mutation (9.8% vs 0%, p = 0.042). 30373548 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE The purpose of this study is to determine whether ABCB5 is highly expressed in BRAF inhibitor-resistant melanoma cells and to evaluate whether ABCB5 is involved in the development of resistance to BRAF inhibitors in cutaneous melanoma. 29929490 2018
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE In cutaneous malignant melanoma, combined treatment with BRAF and MEK inhibitors is associated with high response rates and has been shown to improve progression free as well as overall survival compared to BRAF inhibition alone. 27641727 2017
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy. 29310328 2017
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 Biomarker disease BEFREE Association between dermoscopic and reflectance confocal microscopy features of cutaneous melanoma with BRAF mutational status. 27790766 2017
CUI: C0151779
Disease: Cutaneous Melanoma
Cutaneous Melanoma
0.500 GeneticVariation disease BEFREE The study population comprised 83 patients with advanced cutaneous melanoma presenting with BRAF V600 mutation. 29084636 2017